Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

NCT ID: NCT03834766

Last Updated: 2023-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 130 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-02-06
• Study Completion Date: 2019-10-19

Brief Summary

To evaluate the efficacy of AMPH ER TAB compared to placebo in adult patients with ADHD aged 18 to 60 years.

Detailed Description

This is a randomized, double-blind (DB), placebo-controlled, parallel, study to assess the efficacy and safety of AMPH ER TAB compared to placebo for the treatment of ADHD in adults aged 18 to 60 years.

After Screening and Baseline evaluations are complete, eligible subjects will be randomized in the study to take DB AMPH ER TAB or matching placebo orally once daily in the morning beginning the day after the Baseline visit for 5 weeks. Dose will be titrated on a weekly basis to reach 20 mg per day. Subjects who cannot tolerate the study drug will be discontinued from the study.

A Math Test placement test will be done at Screening or at Baseline. At Visit 5, efficacy assessments will include the administration of serial Math Tests at pre-dose and at 0.5, 1, 2, 4, 8, 10, 12, 13, and 14 hours post-dose (Primary Endpoint) Adult Investigator Symptom Rating Scale (AISRS) and Clinical Global Impression Scale Severity (CGI-S) will be conducted at Baseline and Visits 1 to 5. Digit Symbol Substitution Test (DSST) will be administered at Baseline and Visit 5 (Secondary Endpoints).

Safety assessments will include treatment-emergent adverse events, physical examination, vital signs, body weight, Columbia Suicide Severity Rating Scale (C-SSRS), and direct questioning to assess for sleep, appetite, mood and psychotic events.

Conditions

ADHD

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AMPH ER Tab

Amphetamine Extended Release Tablets 5, 10, 15 and 20 mg

Group Type: ACTIVE_COMPARATOR

AMPH ER Tab 5, 10, 15 and 20 mg

Intervention Type: DRUG

Amphetamine

Matching Placebo

Matching Placebo Tablets 5, 10, 15 and 20 mg

Group Type: PLACEBO_COMPARATOR

AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg

Intervention Type: DRUG

Placebo

Interventions

AMPH ER Tab 5, 10, 15 and 20 mg

Amphetamine

Intervention Type: DRUG

AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg

Placebo

Intervention Type: DRUG

Other Intervention Names

Amphetamine Extended Release Tablets; Amphetamine Extended Release Tablets Matching Placebo

Eligibility Criteria

Inclusion Criteria

1. Male or female aged 18 to 60 years, inclusive at the time of Screening.

2. Diagnosed with ADHD using the DSM-5 criteria based on the Adults ADHD Clinical Diagnostic Scale (ACDS).

3. IQ within normal range based upon clinical opinion of the Investigator.

4. Baseline AISRS total score greater than or equal to 26.

5. Baseline score of 4 or higher in CGI-S.

6. Females who participate in this study will be of childbearing or non-childbearing potential:

• Childbearing potential: Physically capable of becoming pregnant
• Non-childbearing potential:

• Permanently sterile (i.e., both ovaries removed, uterus removed, or bilateral tubal ligation for at least 6 weeks or documented successful hysteroscopic sterilization); and/or
• Post-menopausal (no menstrual period for at least 12 consecutive months without any other medical cause).

7. Females of childbearing potential must be non-lactating and must have a negative serum pregnancy test at Screening.

8. Willing to use acceptable, effective methods of contraception.

9. Be able to attend the clinic regularly and reliably.

10. Be able to understand, read, write, and speak English fluently to complete the study related materials.

11. Be informed of the nature of the study and give written consent prior to any study procedure.

Exclusion Criteria

1. Current or lifetime history of bipolar disorder or any psychotic disorder as established by Mini International Neuropsychiatric Interview (M.I.N.I.) 7.0.2.

2. Current history of major depression, generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, or post-traumatic stress disorder as established by the M.I.N.I. 7.0.2.

3. Known history of chronic medical illnesses including untreated thyroid disease, peripheral vasculopathy, known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, and known family history of sudden death.

4. History of uncontrolled hypertension or a resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg. Subjects with well-controlled hypertension on a stable dose for at least 3 months of anti-hypertensives will be allowed to participate.

5. Have clinically significant findings in vital signs measurements at Screening including:

• Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg
• Heart rate >100 bpm

6. Known history or presence of significant renal or hepatic disease, as indicated by clinical laboratory assessment:

• Liver function test results ≥2 times the upper normal limit
• Abnormal blood urea nitrogen, or creatinine levels

7. Clinically significant abnormal electrocardiogram or cardiac findings on physical examination (including the presence of a pathologic murmur).

8. Use of the following medications within 14 days of Baseline Visit:

• Atomoxetine
• Monoamine oxidase inhibitors (e.g., selegiline, isocarboxazid, phenelzine, tranylcypromine)
• Tricyclic antidepressants (e.g., desipramine, protriptyline).

9. Use of the following medications within 3 days of Baseline Visit:

• Gastrointestinal acidifying agents (e.g., guanethidine, reserpine, glutamic acid hydrochloride [HCl], ascorbic acid)
• Urinary acidifying agents (e.g., ammonium chloride, sodium acid phosphate, methenamine salts).

10. Use of fluoxetine within 30 days of Baseline Visit.

11. Use of stimulant medications within 1 week of Baseline Visit.

12. Planned use of prohibited drugs or agents from the Screening visit through the end of the study.

13. Participation in a clinical study in which an investigational drug was administered within 30 days prior to Screening.

14. Abnormal clinically significant laboratory test values at Screening that, in the opinion of the Medical Monitor or Sponsor, would preclude study participation.

15. Known history of allergy/hypersensitivity to amphetamine or any of the components of AMPH ER TAB.

16. Known history of lack of clinical response to amphetamine based upon Investigator judgment.

17. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.

18. Any uncontrolled medical condition that, in the opinion of Medical Monitor or Sponsor, would preclude study participation.

19. History or presence of alcohol dependence or substance abuse disorder according to DSM-5 or within the last 12 months.

20. Subject's inability or unwillingness to follow directions from the study research staff.

21. Answer of "yes" to questions 4 or 5 of the C-SSRS within the last 2 years.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Premier Research Group plc

UNKNOWN

Sponsor Role: collaborator

Tris Pharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrew J. Cutler, MD

Role: PRINCIPAL_INVESTIGATOR

Meridien Research Inc.

Locations

Meridien Research

Bradenton, Florida, United States

Meridien Research, Inc.

Maitland, Florida, United States

Center for Psychiatry and Behavioral Medicine

Las Vegas, Nevada, United States

Countries

United States

References

Cutler AJ, Childress AC, Pardo A, Duhoux S, Gomeni R, Rafla E, King TR, Kando JC. Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study to Evaluate the Efficacy and Safety of Amphetamine Extended-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry. 2022 Jul 20;83(5):22m14438. doi: 10.4088/JCP.22m14438.

Reference Type: DERIVED

PMID: 35857716 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

TRI108-ADD-400

Identifier Type: -

Identifier Source: org_study_id